Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy

Further Publications NeurologyFurther Publications Psychiatry

Neuroimaging of the component white matter connections and structures within the cerebellar-frontal pathway in posterior fossa tumor survivors

Neuroimage Clin.

Ailion AS, Roberts SR, Crosson B, King TZ

doi: 10.1016/j.nicl.

Multiple Sclerosis

Deep gray matter volume loss drives disability worsening in multiple sclerosis

Ann Neurol.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group

doi: 10.1002/ana.25145.

Aging and Cognitive Functions

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

J Neurol Neurosurg Psychiatry.

Glasmacher SA, Leigh PN, Saha RA

doi: 10.1136/jnnp-2016-314956.

Parkinson’s Disease

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Lancet Neurol.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU

doi: 10.1016/

Aging and Cognitive FunctionsParkinson’s DiseaseDementia

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Mov Disord.

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group

doi: 10.1002/mds.27034.

Multiple Sclerosis

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

Neurology.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T

doi: 10.1212/WNL.

Further Publications NeurologyFurther Publications Psychiatry

Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology

JAMA Neurol.

Heckman MG, Brennan RR, Labbé C, Soto AI, Koga S, DeTure MA, Murray ME, Petersen RC, Boeve BF, van Gerpen JA, Uitti RJ, Wszolek ZK, Rademakers R, Dickson DW, Ross OA

doi: 10.1001/jamaneurol.

Further Publications Neurology

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Lancet Neurol

Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Arise Investigators.

doi: 10.1016/S1474-4422(20)30489-0

Aging and Cognitive FunctionsPsychosis and Schizophrenia

Cognitive performance is associated with gray matter decline in first-episode psychosis

Psychiatry Res.

Dempster K, Norman R, Théberge J, Densmore M, Schaefer B, Williamson P